390 related articles for article (PubMed ID: 31471524)
1. Frequent Loss of IRF2 in Cancers Leads to Immune Evasion through Decreased MHC Class I Antigen Presentation and Increased PD-L1 Expression.
Kriegsman BA; Vangala P; Chen BJ; Meraner P; Brass AL; Garber M; Rock KL
J Immunol; 2019 Oct; 203(7):1999-2010. PubMed ID: 31471524
[TBL] [Abstract][Full Text] [Related]
2. NLRC5/MHC class I transactivator is a target for immune evasion in cancer.
Yoshihama S; Roszik J; Downs I; Meissner TB; Vijayan S; Chapuy B; Sidiq T; Shipp MA; Lizee GA; Kobayashi KS
Proc Natl Acad Sci U S A; 2016 May; 113(21):5999-6004. PubMed ID: 27162338
[TBL] [Abstract][Full Text] [Related]
3. Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation.
Dhatchinamoorthy K; Colbert JD; Rock KL
Front Immunol; 2021; 12():636568. PubMed ID: 33767702
[TBL] [Abstract][Full Text] [Related]
4. T lymphocyte-derived TNF and IFN-γ repress HFE expression in cancer cells.
Reuben A; Godin-Ethier J; Santos MM; Lapointe R
Mol Immunol; 2015 Jun; 65(2):259-66. PubMed ID: 25700349
[TBL] [Abstract][Full Text] [Related]
5. IFN-γ treatment protocol for MHC-I
Stifter K; Krieger J; Ruths L; Gout J; Mulaw M; Lechel A; Kleger A; Seufferlein T; Wagner M; Schirmbeck R
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32868392
[TBL] [Abstract][Full Text] [Related]
6. An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer.
Burr ML; Sparbier CE; Chan KL; Chan YC; Kersbergen A; Lam EYN; Azidis-Yates E; Vassiliadis D; Bell CC; Gilan O; Jackson S; Tan L; Wong SQ; Hollizeck S; Michalak EM; Siddle HV; McCabe MT; Prinjha RK; Guerra GR; Solomon BJ; Sandhu S; Dawson SJ; Beavis PA; Tothill RW; Cullinane C; Lehner PJ; Sutherland KD; Dawson MA
Cancer Cell; 2019 Oct; 36(4):385-401.e8. PubMed ID: 31564637
[TBL] [Abstract][Full Text] [Related]
7. Activation of NF-κB and p300/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentation.
Zhou Y; Bastian IN; Long MD; Dow M; Li W; Liu T; Ngu RK; Antonucci L; Huang JY; Phung QT; Zhao XH; Banerjee S; Lin XJ; Wang H; Dang B; Choi S; Karin D; Su H; Ellisman MH; Jamieson C; Bosenberg M; Cheng Z; Haybaeck J; Kenner L; Fisch KM; Bourgon R; Hernandez G; Lill JR; Liu S; Carter H; Mellman I; Karin M; Shalapour S
Proc Natl Acad Sci U S A; 2021 Feb; 118(8):. PubMed ID: 33602823
[TBL] [Abstract][Full Text] [Related]
8. MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series.
Ugurel S; Spassova I; Wohlfarth J; Drusio C; Cherouny A; Melior A; Sucker A; Zimmer L; Ritter C; Schadendorf D; Becker JC
Cancer Immunol Immunother; 2019 Jun; 68(6):983-990. PubMed ID: 30993371
[TBL] [Abstract][Full Text] [Related]
9. Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNγ signaling in non-small cell lung cancer.
Theelen WSME; Kuilman T; Schulze K; Zou W; Krijgsman O; Peters DDGC; Cornelissen S; Monkhorst K; Sarma P; Sumiyoshi T; Amler LC; Willems SM; Blaauwgeers JLG; van Noesel CJM; Peeper DS; van den Heuvel MM; Kowanetz M
PLoS One; 2019; 14(5):e0216864. PubMed ID: 31125352
[TBL] [Abstract][Full Text] [Related]
10. PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression.
Šmahel M
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28635644
[TBL] [Abstract][Full Text] [Related]
11. Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance.
Deng Y; Xia X; Zhao Y; Zhao Z; Martinez C; Yin W; Yao J; Hang Q; Wu W; Zhang J; Yu Y; Xia W; Yao F; Zhao D; Sun Y; Ying H; Hung MC; Ma L
Nat Commun; 2021 Dec; 12(1):7041. PubMed ID: 34873175
[TBL] [Abstract][Full Text] [Related]
12. Eya3 promotes breast tumor-associated immune suppression via threonine phosphatase-mediated PD-L1 upregulation.
Vartuli RL; Zhou H; Zhang L; Powers RK; Klarquist J; Rudra P; Vincent MY; Ghosh D; Costello JC; Kedl RM; Slansky JE; Zhao R; Ford HL
J Clin Invest; 2018 Jun; 128(6):2535-2550. PubMed ID: 29757193
[TBL] [Abstract][Full Text] [Related]
13. Mammary-tumor-educated B cells acquire LAP/TGF-β and PD-L1 expression and suppress anti-tumor immune responses.
Zhang Y; Morgan R; Chen C; Cai Y; Clark E; Khan WN; Shin SU; Cho HM; Al Bayati A; Pimentel A; Rosenblatt JD
Int Immunol; 2016 Sep; 28(9):423-33. PubMed ID: 26895637
[TBL] [Abstract][Full Text] [Related]
14. The tumour suppressor Fhit positively regulates MHC class I expression on cancer cells.
Romero I; Martinez M; Garrido C; Collado A; Algarra I; Garrido F; Garcia-Lora AM
J Pathol; 2012 Jul; 227(3):367-79. PubMed ID: 22451343
[TBL] [Abstract][Full Text] [Related]
15. Loss of VGLL4 suppresses tumor PD-L1 expression and immune evasion.
Wu A; Wu Q; Deng Y; Liu Y; Lu J; Liu L; Li X; Liao C; Zhao B; Song H
EMBO J; 2019 Jan; 38(1):. PubMed ID: 30396996
[TBL] [Abstract][Full Text] [Related]
16. MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation.
Fang Y; Wang L; Wan C; Sun Y; Van der Jeught K; Zhou Z; Dong T; So KM; Yu T; Li Y; Eyvani H; Colter AB; Dong E; Cao S; Wang J; Schneider BP; Sandusky GE; Liu Y; Zhang C; Lu X; Zhang X
J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 32990678
[TBL] [Abstract][Full Text] [Related]
17. Steady-state antigen scavenging, cross-presentation, and CD8+ T cell priming: a new role for lymphatic endothelial cells.
Hirosue S; Vokali E; Raghavan VR; Rincon-Restrepo M; Lund AW; Corthésy-Henrioud P; Capotosti F; Halin Winter C; Hugues S; Swartz MA
J Immunol; 2014 Jun; 192(11):5002-11. PubMed ID: 24795456
[TBL] [Abstract][Full Text] [Related]
18. Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1-Resistant Tumors Leading to Tumor Eradication.
Arina A; Karrison T; Galka E; Schreiber K; Weichselbaum RR; Schreiber H
Cancer Immunol Res; 2017 Feb; 5(2):127-136. PubMed ID: 28077434
[TBL] [Abstract][Full Text] [Related]
19. Tumor immune evasion through loss of MHC class-I antigen presentation.
Sari G; Rock KL
Curr Opin Immunol; 2023 Aug; 83():102329. PubMed ID: 37130455
[TBL] [Abstract][Full Text] [Related]
20. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
